{Reference Type}: Controlled Clinical Trial
{Title}: Development and evaluation of a live attenuated camelpox vaccine from a local field isolate of the virus.
{Author}: Abdellatif MM;Ibrahim AA;Khalafalla AI;
{Journal}: Rev Sci Tech
{Volume}: 33
{Issue}: 3
{Year}: 12 2014
{Factor}: 0.836
{DOI}: 10.20506/rst.33.3.2321
{Abstract}: A strain of camelpox virus (CMLV) isolated in the Sudan was attenuated by serial passage in Vero cell monolayers for use as a future vaccine strain. The safety and potency of passage 115 virus (designated Sudan CMLV/115) was tested. Camels inoculated with CMLV/115 showed no clinical disease or skin lesions, developed low-level antibodies and cell-mediated immune response and resisted challenge with virulent wild-type CMLV. Field testing of the candidate vaccine showed that the developed vaccine induces immune response and is safe for young and pregnant camels.